Abstract
BackgroundDipeptidyl peptidase-4 (DPP4) regulates blood glucose levels and inflammation, and it is also implicated in the pathophysiological process of myocardial infarction (MI). Plasma DPP4 activity (DPP4a) may provide prognostic information regarding outcomes for ST-segment elevation MI (STEMI) patients.MethodsBlood samples were obtained from 625 consecutively admitted, percutaneous coronary intervention-treated STEMI patients with a mean age of 57 years old. DPP4a was quantified using enzymatic assays.ResultsThe median follow-up period was 30 months. Multivariate Cox-regression analyses (adjusted for confounding variables) showed that a 1 U/L increase of DPP4a did not associate with risks of major adverse cardiac or cerebrovascular events (MACCE), cardiovascular mortality, MI, heart failure readmission, stroke, non-cardiovascular mortality and repeated revascularization. However, in a subset of 149 diabetic STEMI patients, DPP4a associated with an increased risk of MACCE (HR 1.16; 95% CI 1.04–1.30; p = 0.01).ConclusionsDPP4a did not associate with cardiovascular events and non-cardiovascular mortality in non-diabetic STEMI patients. However, DPP4a may be associated with future MACCE in diabetic STEMI patients.Trial registration NCT03046576, registered on 5 February, 2017, retrospectively registered
Highlights
Dipeptidyl peptidase-4 (DPP4) regulates blood glucose levels and inflammation, and it is impli‐ cated in the pathophysiological process of myocardial infarction (MI)
DPP4 activity (DPP4a) positively associated with current smoking status, and levels of ALT and AST (Table 1)
This study demonstrates a lack of evidence that DPP4a predicted major adverse cardiac or cerebro‐ vascular events (MACCE) in non-diabetic segment elevation MI (STEMI) patients receiving Percutaneous coronary intervention (PCI) treatment
Summary
Dipeptidyl peptidase-4 (DPP4) regulates blood glucose levels and inflammation, and it is impli‐ cated in the pathophysiological process of myocardial infarction (MI). Plasma DPP4 activity (DPP4a) may provide prognostic information regarding outcomes for ST-segment elevation MI (STEMI) patients. Widespread expression of DPP4 on the surface of myocardial and endothelial cells, and the non-enzymatic function of it as a signaling and binding protein suggest a function in cardiovascular regulation [2]. The DPP4 inhibitor saxagliptin led to a 27% increase in hospitalization for HF in diabetic patients who had a history of, or were at risk for, cardiovascular events [3]. Use of DPP4 exists in a soluble form in the plasma, where it is thought to be shed from the membranes of endothelial cells, while maintaining enzymatic activity [8]. Increased plasma DPP4 activity (DPP4a) predicted both sub-clinical and new-onset atherosclerotic events [9, 10].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
